Reuters -- A second generic version of Sanofi-Aventis’s (SASY.PA) blood-clot drug Lovenox is likely to reach the U.S. market this year, intensifying competition and pushing down prices, a leading analyst said on Thursday.
Reuters -- A second generic version of Sanofi-Aventis’s (SASY.PA) blood-clot drug Lovenox is likely to reach the U.S. market this year, intensifying competition and pushing down prices, a leading analyst said on Thursday.
